Hms Capital Management, LLC Bristol Myers Squibb CO Transaction History

Hms Capital Management, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 20, 2022	SELL	$61.48 - $73.72 $323,938 - $388,430	-5,269 Closed	0 $0
Q4 2021 Feb 03, 2022	SELL	$53.63 - $62.52 $24,133 - $28,134	-450 Reduced 7.87%	5,269 $329,000
Q3 2021 Nov 02, 2021	BUY	$59.17 - $69.31 $2,248 - $2,633	38 Added 0.67%	5,719 $338,000
Q2 2021 Jul 13, 2021	BUY	$61.91 - $67.42 $36,588 - $39,845	591 Added 11.61%	5,681 $380,000
Q1 2021 Apr 12, 2021	SELL	$59.34 - $66.74 $67,706 - $76,150	-1,141 Reduced 18.31%	5,090 $321,000
Q4 2020 Jan 29, 2021	SELL	$57.74 - $65.43 $50,060 - $56,727	-867 Reduced 12.21%	6,231 $386,000
Q3 2020 Oct 20, 2020	SELL	$57.43 - $63.64 $6,259 - $6,936	-109 Reduced 1.51%	7,098 $428,000
Q2 2020 Jul 31, 2020	BUY	$54.82 - $64.09 $144,834 - $169,325	2,642 Added 57.88%	7,207 $424,000
Q1 2020 Apr 27, 2020	BUY	$46.4 - $67.43 $211,816 - $307,817	4,565 New	4,565 $254,000
Q4 2019 Jan 29, 2020	SELL	$49.21 - $64.19 $238,176 - $310,679	-4,840 Closed	0 $0
Q3 2019 Oct 15, 2019	BUY	$42.77 - $50.71 $164,236 - $194,726	3,840 Added 384.0%	4,840 $245,000
Q2 2019 Jul 12, 2019	BUY	$44.62 - $49.34 $44,620 - $49,340	1,000 New	1,000 $45,000
Q1 2019 Apr 24, 2019	SELL	$45.12 - $53.8 $436,761 - $520,784	-9,680 Closed	0 $0
Q4 2018 Jan 14, 2019	BUY	$48.76 - $63.23 $235,998 - $306,033	4,840 Added 100.0%	9,680 $503,000
Q3 2018 Nov 02, 2018	BUY	$55.19 - $62.25 $55,190 - $62,250	1,000 Added 26.04%	4,840 $300,000
Q2 2018 Aug 06, 2018	BUY	$50.53 - $62.98 $194,035 - $241,843	3,840 New	3,840 $213,000

2,536

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Hms Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Hms Capital Management, LLC with notifications on news.